-
EP2729144
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2729144
| EP2729144 - TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 04.11.2015 Database last updated on 02.11.2024 | Most recent event Tooltip | 04.11.2015 | Application deemed to be withdrawn | published on 02.12.2015 [2015/49] | Applicant(s) | For all designated states Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 / US | [2014/20] | Inventor(s) | 01 /
EL-HARIRY, Iman One Back Bay 135 Clarendon Street Apt 14U Boston, MA 02116 / US | 02 /
PROIA, David 30 Silver Lake Avenue Newton, MA 02458 / US | 03 /
VUKOVIC, Vojo 51 Wildwood Street Winchester, MA 01890 / US | [2014/20] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2014/20] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham, NG1 5GG / GB | Application number, filing date | 12735423.1 | 09.07.2012 | WO2012US45978 | Priority number, date | US201161505322P | 07.07.2011 Original published format: US 201161505322 P | US201161549941P | 21.10.2011 Original published format: US 201161549941 P | US201261623762P | 13.04.2012 Original published format: US 201261623762 P | [2014/20] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2013006864 | Date: | 10.01.2013 | Language: | EN | [2013/02] | Type: | A2 Application without search report | No.: | EP2729144 | Date: | 14.05.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.01.2013 takes the place of the publication of the European patent application. | [2014/20] | Search report(s) | International search report - published on: | EP | 25.04.2013 | Classification | IPC: | A61K31/4196, A61K31/4439, A61P35/00 | [2014/20] | CPC: |
A61K31/4196 (EP,US);
A61K31/337 (EP,US);
A61K31/417 (EP,US);
A61K31/4545 (EP,US);
A61K31/519 (EP,US);
A61K31/675 (EP,US);
A61K33/243 (EP,US);
A61K45/06 (US);
A61P35/00 (EP);
C07D403/04 (EP,US)
(-)
| C-Set: |
A61K31/4196, A61K2300/00 (EP,US);
A61K31/444, A61K2300/00 (US,EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/20] | Extension states | BA | 05.02.2014 | ME | 05.02.2014 | Title | German: | BEHANDLUNG VON KREBS MIT HSP90-HEMMENDEN VERBINDUNGEN | [2014/20] | English: | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | [2014/20] | French: | TRAITEMENT DU CANCER AU MOYEN DE COMPOSÉS INHIBITEURS DE HSP90 | [2014/20] | Entry into regional phase | 05.02.2014 | National basic fee paid | 05.02.2014 | Designation fee(s) paid | 05.02.2014 | Examination fee paid | Examination procedure | 05.02.2014 | Examination requested [2014/20] | 04.09.2014 | Amendment by applicant (claims and/or description) | 12.12.2014 | Despatch of a communication from the examining division (Time limit: M06) | 23.06.2015 | Application deemed to be withdrawn, date of legal effect [2015/49] | 27.07.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2015/49] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 12.12.2014 | Fees paid | Renewal fee | 28.07.2014 | Renewal fee patent year 03 | 27.07.2015 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2007139951 (SYNTA PHARMACEUTICALS CORP [US], et al) [X] 1,2,9,21,22 * See claims 220-259 and see compound at page 206, entry 226: The relevant compounds and their use for the treatment of cancers expressing the NPM-ALK fusion protein: *; | [A]WO2008153730 (SYNTA PHARMACEUTICALS CORP [US], et al) [A] 1-16,21-23 * See claims and see compound at page 191, entry 226: The relevant compounds and their use for the treatment of cancers expressing the c-met fusion protein *; | [Y]WO2009102446 (BRIGHAM & WOMENS HOSPITAL [US], et al) [Y] 1-16,21-23 * See claims 1, 48, 55: assay for identifying EML4-ALK mutations, and methods of treatment of cancers associated with EML4-ALK mutation using, inter alia crizotinib *; | [Y]WO2011049946 (SYNTA PHARMACEUTICALS CORP [US], et al) [Y] 1-16,21-23* See claims: the relevant compounds to treat NSCLC cancer, in combination with other agents *; | [XO] - Geoffrey Shapiro, "Phase II study of the Hsp90 inhibitor ganetespib as monotherapy in patients with advanced NSCLC", (201106), INTERNET-U-Tube, URL: http://www.youtube.com/watch?v=UX8fEZbF1bk, (20120913) [XO] 1-5,7,8 * See the presentation from Dr Shapiro, registered at the 2011 ASCO meeting (June 3 - 7, 2011) which was uploaded in the internet on 27.06.2011, describing the positive results of the clinical study in which the compound ganetespib was administered to EML4-Alk positive NSCLC patients and the use of such compound for treating patients resistant to crizotinib * | [XP] - Reichert et al, "Ganetespib: An effective strategy to overcomecrizotinib resistance in ALK-driven cancers", (20120421), INTERNET, URL: http://www.syntapharma.com/Documents/Ganetespib_ALK_Euro_IASLC_2012_Poster.pdf, (20120914), XP002683507 [XP] 1-8,12,13,16,21-23 * See abstract: Ganetespib overcomes crizotinib resistance NSCLC cancer patients expressiong the EML4-Alk mutation. Ganetespib also produces synergistic activity with crizotinib * | [X] - YING WEIWEN ET AL, "Preclinical Evaluation of A Potent 2(nd) Generation Small-Molecule Hsp90 Inhibitor STA-9090 In Hematological Cell Lines", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 116, no. 21, ISSN 0006-4971, (20101101), page 1194, (20101119), XP009162837 [X] 1,2,9,21,22 * See abstract: STA-9090 (ganetespib), the preferred compounds of the invention has utility in the treatment of NSCLC and is able to destabilise NPM-ALK and other oncogenic kinases overexpressed in mutated hematologic cancers * | [Y] - RYOHEI KATAYAMA ET AL, "Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 108, no. 18, doi:10.1073/PNAS.1019559108, ISSN 0027-8424, (20110503), pages 7535 - 7540, (20110418), XP002672743 [Y] 1-16,21-23 * See abstract, results and discussion: crizotinib resistance in NSCLC cancer is associated with amplification of the EML4-ALK gene and can be overcome with Alk inhibitors and Hsp90 inhibitors (see pages 3-4 and conclusions at page 6) * DOI: http://dx.doi.org/10.1073/pnas.1019559108 | [Y] - NWIZU T ET AL, "CRIZOTINIB ALK/Met inhibitor Oncolytic", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, (20110201), vol. 36, no. 2, doi:10.1358/DOF.2011.36.2.1584112, ISSN 0377-8282, pages 91 - 99, XP009154039 [Y] 1-16,21-23 * See summary, clinical trials and table 1: crizotinib is active in NSCLC cancers with EML4-ALK gene rearrangements and is also active against tyrosine-protein kinase Met * DOI: http://dx.doi.org/10.1358/dof.2011.36.2.1584112 | Examination | - WHO, "International Nonproprietary Names for Pharmaceutical Substances (INN)", (20110630), URL: http://www.who.int/medicines/publications/druginformation/innlists/PL105.pdf?ua=1 | - DAVID A PROIA ET AL, "Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, (20110414), vol. 6, no. 4, doi:10.1371/JOURNAL.PONE.0018552, ISSN 1932-6203, pages E18552 - 1, XP002674768 DOI: http://dx.doi.org/10.1371/journal.pone.0018552 | by applicant | US3536809 | US3598123 | CH542802 | US3845770 | US3916899 | US4008719 | US5059595 | US5073543 | US5120548 | US5354556 | US5529925 | US5591767 | US5639476 | US5674533 | US5733566 | US5770421 | US2006167070 | WO2009023211 | US7700339 | US2011110923 | - NATURE REVIEWS CLINICAL ONCOLOGY, (201205), vol. 9, pages 268 - 277 | - BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY, (1995), vol. 172-178, pages 949 - 982 | - PALMER ET AL., BIOCHEM. J., (2009), pages 345 - 361 | - KOIVUNEN ET AL., CLIN. CAN. RES., (2008), vol. 14, pages 4275 - 4283 | - ANDERSON, EXPERT REV. MOL. DIAGN., (2011), vol. 11, no. 6, pages 635 - 642 | - PINTO ET AL., CANCER GENETICS, (2011), vol. 204, pages 439 - 446 | - REKHTMAN ET AL., CLIN CANCER RES, (2012), vol. 18, pages 1167 - 1176 | - MASSARELLI ET AL., CLIN CANCER RES, (2007), vol. 13, pages 2890 - 2896 | - LAMY ET AL., MODERN PATHOLOGY, (2011), vol. 24, pages 1090 - 1100 | - BALSCHUN ET AL., EXPERT REV. MOL. DIAGN., (2011), vol. 11, no. 8, pages 799 - 802 | - VAKIANI ET AL., J PATHOL, (2011), vol. 223, pages 219 - 229 | - OKUDELA ET AL., PATHOLOGY INTERNATIONAL, (2010), vol. 60, pages 651 - 660 | - JOHN ET AL., ONCOGENE, (2009), vol. 28, pages S14 - S23 | - QIAN ET AL., CANCER RESEARCH, (2002), vol. 62, pages 589 - 596 | - MA ET AL., CANCER AND METASTASIS REVIEWS, (2003), vol. 22, pages 309 - 325 | - CHRISTENSEN ET AL., CANCER RESEARCH, (2003), vol. 63, pages 7345 - 7355 | - BERTHOU ET AL., ONCOGENE, (2004), vol. 23, pages 5387 - 5393 |